Matches in SemOpenAlex for { <https://semopenalex.org/work/W2022805390> ?p ?o ?g. }
- W2022805390 endingPage "820" @default.
- W2022805390 startingPage "817" @default.
- W2022805390 abstract "In a study of patients with BOO and an overactive bladder, authors from Seoul and Pittsburgh compared the use of doxazosin with or without tolterodine. The combination of the two drugs was helpful in most patients, but doxazosin alone was also effective. The impact of controlled‐release delivery of drugs on patient comfort has been considerable. The paper by authors from Germany and the USA describes the effect of the leader in this field on the pharmacokinetics of oxybutynin at different dosages. They confirm that this technology facilitates the severity‐dependent treatment of the overactive bladder with flexible‐dose adaptations to patient requirements. There are two papers on virtual cystoscopy, in one case using CT and in the other IVU. The authors report that virtual cystoscopy is valuable in investigating patients, drawing attention to its benefits and shortcomings. OBJECTIVE To assess the efficacy of combined treatment with doxazosin and tolterodine, as although α‐blockers are commonly used and generally effective in men with symptomatic bladder outlet obstruction (BOO), a subset of men with BOO and overactive bladder (OAB) symptoms often complain of persistent symptoms. PATIENTS AND METHODS In a prospective study of 144 consecutive men with BOO at one tertiary urology centre, all had a baseline pressure‐flow urodynamic study and were then subdivided into those with BOO or BOO + OAB, based on absence or presence of involuntary detrusor contractions. The Abrams–Griffiths nomogram was used to determine obstructive BOO. After the initial evaluation, all patients were treated with doxazosin 4 mg/day for 3 months. In patients with no symptomatic improvement, tolterodine 2 mg twice daily was added for an additional 3 months. RESULTS Of the 144 patients, 76 (53%) were diagnosed as having BOO and 68 (47%) BOO + OAB. The patients with BOO + OAB were older ( P < 0.05) and had a higher International Prostate Symptom Score. After 3 months of treatment with doxazosin, 60 (79%) with BOO and 24 (35%) BOO + OAB reported a symptomatic improvement. In those patients with no improvement, six of 16 with BOO and 32 of 44 (73%) with BOO + OAB improved after adding tolterodine. Acute urinary retention developed in only two of 60 men (3.3%) treated with the combined therapy. CONCLUSIONS About half of men with symptomatic BOO had an OAB; while about three‐quarters of men with symptomatic BOO and no OAB improved with doxazosin, only a third with BOO + OAB were helped with doxazosin alone. Combining tolterodine with doxazosin was effective in three‐quarters of men with BOO + OAB. Overall, most men with BOO with or with no OAB were helped with doxazosin alone or with the addition of tolterodine." @default.
- W2022805390 created "2016-06-24" @default.
- W2022805390 creator A5008383067 @default.
- W2022805390 creator A5041633203 @default.
- W2022805390 creator A5046388896 @default.
- W2022805390 creator A5049642187 @default.
- W2022805390 creator A5063822726 @default.
- W2022805390 creator A5076037136 @default.
- W2022805390 date "2004-10-01" @default.
- W2022805390 modified "2023-10-16" @default.
- W2022805390 title "Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder" @default.
- W2022805390 cites W1555940045 @default.
- W2022805390 cites W1975391576 @default.
- W2022805390 cites W1976469925 @default.
- W2022805390 cites W2004039836 @default.
- W2022805390 cites W2011746657 @default.
- W2022805390 cites W2017697402 @default.
- W2022805390 cites W2020523232 @default.
- W2022805390 cites W2036799618 @default.
- W2022805390 cites W2056571407 @default.
- W2022805390 cites W2068662093 @default.
- W2022805390 cites W2078997630 @default.
- W2022805390 cites W2123416699 @default.
- W2022805390 cites W2133928348 @default.
- W2022805390 cites W2141451257 @default.
- W2022805390 cites W2395749492 @default.
- W2022805390 cites W2410175384 @default.
- W2022805390 cites W2416973342 @default.
- W2022805390 doi "https://doi.org/10.1111/j.1464-410x.2004.05039.x" @default.
- W2022805390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15476515" @default.
- W2022805390 hasPublicationYear "2004" @default.
- W2022805390 type Work @default.
- W2022805390 sameAs 2022805390 @default.
- W2022805390 citedByCount "238" @default.
- W2022805390 countsByYear W20228053902012 @default.
- W2022805390 countsByYear W20228053902013 @default.
- W2022805390 countsByYear W20228053902014 @default.
- W2022805390 countsByYear W20228053902015 @default.
- W2022805390 countsByYear W20228053902016 @default.
- W2022805390 countsByYear W20228053902017 @default.
- W2022805390 countsByYear W20228053902018 @default.
- W2022805390 countsByYear W20228053902019 @default.
- W2022805390 countsByYear W20228053902020 @default.
- W2022805390 countsByYear W20228053902021 @default.
- W2022805390 countsByYear W20228053902022 @default.
- W2022805390 countsByYear W20228053902023 @default.
- W2022805390 crossrefType "journal-article" @default.
- W2022805390 hasAuthorship W2022805390A5008383067 @default.
- W2022805390 hasAuthorship W2022805390A5041633203 @default.
- W2022805390 hasAuthorship W2022805390A5046388896 @default.
- W2022805390 hasAuthorship W2022805390A5049642187 @default.
- W2022805390 hasAuthorship W2022805390A5063822726 @default.
- W2022805390 hasAuthorship W2022805390A5076037136 @default.
- W2022805390 hasConcept C121608353 @default.
- W2022805390 hasConcept C126322002 @default.
- W2022805390 hasConcept C126894567 @default.
- W2022805390 hasConcept C142724271 @default.
- W2022805390 hasConcept C204787440 @default.
- W2022805390 hasConcept C2776235491 @default.
- W2022805390 hasConcept C2777590997 @default.
- W2022805390 hasConcept C2777844464 @default.
- W2022805390 hasConcept C2778769751 @default.
- W2022805390 hasConcept C2778941218 @default.
- W2022805390 hasConcept C2779478474 @default.
- W2022805390 hasConcept C2780070792 @default.
- W2022805390 hasConcept C2780546585 @default.
- W2022805390 hasConcept C2781020410 @default.
- W2022805390 hasConcept C71924100 @default.
- W2022805390 hasConcept C77411442 @default.
- W2022805390 hasConcept C84393581 @default.
- W2022805390 hasConceptScore W2022805390C121608353 @default.
- W2022805390 hasConceptScore W2022805390C126322002 @default.
- W2022805390 hasConceptScore W2022805390C126894567 @default.
- W2022805390 hasConceptScore W2022805390C142724271 @default.
- W2022805390 hasConceptScore W2022805390C204787440 @default.
- W2022805390 hasConceptScore W2022805390C2776235491 @default.
- W2022805390 hasConceptScore W2022805390C2777590997 @default.
- W2022805390 hasConceptScore W2022805390C2777844464 @default.
- W2022805390 hasConceptScore W2022805390C2778769751 @default.
- W2022805390 hasConceptScore W2022805390C2778941218 @default.
- W2022805390 hasConceptScore W2022805390C2779478474 @default.
- W2022805390 hasConceptScore W2022805390C2780070792 @default.
- W2022805390 hasConceptScore W2022805390C2780546585 @default.
- W2022805390 hasConceptScore W2022805390C2781020410 @default.
- W2022805390 hasConceptScore W2022805390C71924100 @default.
- W2022805390 hasConceptScore W2022805390C77411442 @default.
- W2022805390 hasConceptScore W2022805390C84393581 @default.
- W2022805390 hasIssue "6" @default.
- W2022805390 hasLocation W20228053901 @default.
- W2022805390 hasLocation W20228053902 @default.
- W2022805390 hasOpenAccess W2022805390 @default.
- W2022805390 hasPrimaryLocation W20228053901 @default.
- W2022805390 hasRelatedWork W1672203549 @default.
- W2022805390 hasRelatedWork W1983703699 @default.
- W2022805390 hasRelatedWork W1996519920 @default.
- W2022805390 hasRelatedWork W2069015817 @default.
- W2022805390 hasRelatedWork W2069813136 @default.
- W2022805390 hasRelatedWork W2087498132 @default.